Premium
Renin‐angiotensin system is an important factor in hormone refractory prostate cancer
Author(s) -
Uemura Hiroji,
Hasumi Hisashi,
Ishiguro Hitoshi,
Teranishi Junichi,
Miyoshi Yasuhide,
Kubota Yoshinobu
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20407
Subject(s) - lncap , prostate cancer , prostate , endocrinology , dihydrotestosterone , medicine , angiotensin ii , angiotensin ii receptor type 1 , renin–angiotensin system , androgen receptor , androgen , hormone , cancer research , cancer , biology , receptor , blood pressure
Abstract Background The aim of this study was to perform a comprehensive evaluation of the renin‐angiotensin system (RAS) in prostate cancer. Methods We investigated the expression of RAS components in prostate cancer cells treated with hormonal agents. Real‐time PCR data showed the expression of the AT 1 receptor, angiotensin I converting enzyme (ACE), and angiotensin I/II (Ang‐I/II) precursor in all 87 prostate tissue samples. Results Expression of these genes in hormone refractory prostate cancer (HRPC) was significantly higher than that in normal prostate tissue and untreated prostate cancer tissue. Western blot showed that protein expression of the AT 1 receptor and Ang‐I/II was enhanced in LNCaP cells cultivated in steroid‐free medium. When LNCaP cells were stimulated with dihydrotestosterone (DHT), estradiol (E2), dexamethasone (DEX), or anti‐androgen drugs, protein expression of the AT 1 receptor and Ang‐I/II was augmented. Conclusions The present data suggest that prostatic RAS is overexpressed in HRPC tissue, and expression of its components is influenced by several kinds of hormonal stimulation. Prostate © 2006 Wiley‐Liss, Inc.